SCHEMBL6497506

SCHEMBL6497506

CCOC(=O)CCCOc1ccc2nc(C)n(Cc3ncc(C(F)(F)F)cc3Cl)c2c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
P2RY12 Q9H244 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PLA2G2A P14555 3/20 0.41
ALOX5AP P20292 2/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
PDK2 Q15119 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
CYSLTR2 Q9NS75 1/20 0.38
CYSLTR1 Q9Y271 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490952 0.91 ALOX5AP (0.43) PDE3BPDE3AP2RY12PLA2G2AALOX5AP
SCHEMBL6502820 0.87 ALOX5AP (0.42) L3MBTL1ALOX5APHPGDMEN1KMT2A
SCHEMBL6489825 0.87 L3MBTL1 (0.43) L3MBTL1PLA2G2AHPGDMEN1KMT2A
SCHEMBL6920280 0.82 PDE3B (0.42) PDE3BPDE3AP2RY12ALOX5APMEN1
SCHEMBL6501253 0.80 L3MBTL1 (0.42) L3MBTL1HPGDMEN1KMT2APDK2
SCHEMBL6498632 0.80 PDE3B (0.48) PDE3BPDE3AP2RY12PLA2G2AALOX5AP
SCHEMBL6495068 0.79 PPARG (0.52) PDE3BPDE3AP2RY12PLA2G2AALOX5AP
SCHEMBL6488591 0.79 ALOX5AP (0.44) PLA2G2AALOX5AP
SCHEMBL6497461 0.78 PPARG (0.49) PDE3BPDE3AP2RY12PLA2G2AALOX5AP
SCHEMBL6487805 0.78 KDM4E (0.42) L3MBTL1MEN1KMT2ANPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PDE3B 411/4885PDE3A 733/4885P2RY12 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.